Blau Farmacêutica Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Blau Farmacêutica de 18.2% y 11.7% por año respectivamente. Se prevé que el BPA crezca en un 17.2% al año. Se espera que la rentabilidad financiera sea de 13.5% en 3 años.

Información clave

18.2%

Tasa de crecimiento de los beneficios

17.2%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	31.7%
Tasa de crecimiento de los ingresos	11.7%
Rentabilidad financiera futura	13.5%
Cobertura de analistas	Good
Última actualización	13 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 07

Recent updates

Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 07

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 25% Share Price Surge Not Quite Adding Up

Nov 06

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Aug 29

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

Jun 28

Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

Feb 01

What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

May 14

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Feb 24

Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Oct 14

Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Aug 17

Previsiones de crecimiento de beneficios e ingresos

BOVESPA:BLAU3 - Estimaciones futuras de los analistas y datos financieros pasados (BRL Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	2,173	325	48	361	8
12/31/2025	1,937	283	33	355	8
12/31/2024	1,780	237	89	423	2
9/30/2024	1,686	187	88	333	N/A
6/30/2024	1,575	216	2	238	N/A
3/31/2024	1,474	240	20	284	N/A
12/31/2023	1,373	250	-44	221	N/A
9/30/2023	1,352	317	-7	253	N/A
6/30/2023	1,351	312	8	262	N/A
3/31/2023	1,352	354	33	229	N/A
12/31/2022	1,407	363	-8	172	N/A
9/30/2022	1,390	314	104	267	N/A
6/30/2022	1,348	313	96	252	N/A
3/31/2022	1,354	301	-21	137	N/A
12/31/2021	1,366	325	-24	154	N/A
9/30/2021	1,354	354	9	166	N/A
6/30/2021	1,338	335	-13	146	N/A
3/31/2021	1,289	309	13	208	N/A
12/31/2020	1,182	254	53	224	N/A
9/30/2020	1,066	238	-17	183	N/A
6/30/2020	1,029	214	76	245	N/A
3/31/2020	1,008	203	103	217	N/A
12/31/2019	978	200	125	221	N/A
9/30/2019	987	186	72	131	N/A
6/30/2019	938	177	24	82	N/A
3/31/2019	819	129	19	77	N/A
12/31/2018	782	123	32	83	N/A
9/30/2018	677	90	27	67	N/A
6/30/2018	616	78	N/A	90	N/A
3/31/2018	634	110	N/A	137	N/A
12/31/2017	618	103	N/A	127	N/A
12/31/2016	431	32	N/A	46	N/A
12/31/2015	379	22	N/A	42	N/A
12/31/2014	299	17	N/A	14	N/A
12/31/2013	271	15	N/A	-3	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (18.2% al año) de BLAU3 es superior a la tasa de ahorro (10.4%).

Beneficios vs. Mercado: Se prevé que los beneficios (18.2% al año) de BLAU3 crezcan más rápidamente que el mercado BR (12.5% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de BLAU3 crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (11.7% al año) de BLAU3 crezcan más rápidamente que los del mercado BR (7.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 11.7% al año) de BLAU3 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de BLAU3 sea baja dentro de 3 años (13.5%).

Blau Farmacêutica Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates

Consensus EPS estimates increase by 27%

Price target increased by 11% to R$14.88

Price target increased by 10% to R$14.00

Price target decreased by 9.1% to R$14.29

Price target decreased by 14% to R$15.71

Recent updates

Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 27%

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 25% Share Price Surge Not Quite Adding Up

Price target increased by 11% to R$14.88

Investor sentiment improves as stock rises 15%

Price target increased by 10% to R$14.00

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 15%

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

New minor risk - Profit margin trend

First quarter 2024 earnings released: EPS: R$0.23 (vs R$0.29 in 1Q 2023)

Price target decreased by 9.1% to R$14.29

Upcoming dividend of R$0.014 per share

Full year 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 14% to R$15.71

Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

Investor sentiment deteriorates as stock falls 16%

Consensus EPS estimates fall by 14%

Blau Farmacêutica S.A. to Report Q2, 2024 Results on Aug 06, 2024

Price target decreased by 7.9% to R$19.86

Consensus revenue estimates fall by 16%

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings: Revenues miss analyst expectations

Consensus EPS estimates fall by 12%

Blau Farmacêutica S.A. to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.4% to R$27.39

Price target decreased by 7.1% to R$29.17

Price target decreased by 7.4% to R$31.40

What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

Consensus revenue estimates decrease by 12%

Consensus EPS estimates fall by 19%

First quarter 2023 earnings released: EPS: R$0.29 (vs R$0.34 in 1Q 2022)

Price target decreased by 7.7% to R$33.91

Price target decreased by 8.3% to R$34.58

Investor sentiment deteriorates as stock falls 15%

Upcoming dividend of R$0.052 per share at 3.0% yield

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: Revenues miss analyst expectations

Now 20% undervalued after recent price drop

Insufficient new directors

Third quarter 2022 earnings: Revenues miss analyst expectations

Now 20% undervalued

Now 22% undervalued

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Price target decreased to R$37.57

Now 21% undervalued after recent price drop

First quarter 2022 earnings: Revenues in line with analyst expectations

Insufficient new directors

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Full year 2021 earnings: Revenues in line with analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Investor sentiment deteriorated over the past week

Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Second quarter 2021 earnings released: EPS R$0.56 (vs R$0.50 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS R$0.58 (vs R$0.21 in 1Q 2020)

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas